Oklahoma legislators have passed a proposal that would greatly increase the number of qualifying conditions for access to medical cannabidiol (CBD)-only cannabis medications.
House lawmakers voted 89-6 this week to approve House Bill 2835. The bill now moves to the Senate.
The bill would afford legal protections regarding the possession of CBD-infused cannabis products to people suffering from Alzheimer’s disease, dementia, chronic pain, neuropathic pain, spasticity from multiple sclerosis or paraplegia, intractable nausea and vomiting, chronic wasting diseases, attention deficit with hyperactivity disorder, or bipolar affective disorder, according to The Daily Chronic.
Currently, only people suffering from intractable forms of epilepsy can legally access CBD-infused products in Oklahoma.
Oklahoma legislators passed a bill last year that protects children suffering from intractable epilepsy from being legally prosecuted for the possession of liquid CBD medications if they have a doctor’s recommendation. That bill, known as Katie and Cayman’s law, allowed children under the age of 18 to participate in medical trials, conducted by university medical centers, to study the effectiveness of cannabidiol in treating intractable pediatric epilepsy.
These CBD-only liquid cannabis products must contain less than 0.3% tetrahydrocannabinol (THC). Under current Oklahoma law, the cultivation of CBD products remains prohibited in-state.